| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Total Expenses - EUR | 138 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Gross Profit/Loss - EUR | -138 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Net Profit/Loss - EUR | -138 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
Check the financial reports for the company - Ultramarine Embryogenesis S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | -1.020 | -1.009 | -992 | -974 | 0 | 0 | 0 | 0 | - | - |
| Current Assets | 35.101 | 34.743 | 34.155 | 33.528 | 30.658 | 30.077 | 29.410 | 29.501 | - | - |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Receivables | 29.859 | 29.555 | 29.055 | 28.521 | 30.422 | 29.845 | 882 | 0 | - | - |
| Cash | 5.241 | 5.188 | 5.100 | 5.007 | 237 | 232 | 28.528 | 29.501 | - | - |
| Shareholders Funds | 32.730 | 32.396 | 31.848 | 31.264 | 30.658 | 30.077 | 29.410 | 29.501 | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | - | - |
| Debts | 1.351 | 1.337 | 1.314 | 1.290 | 0 | 0 | 0 | 0 | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3314 - 3314" | |||||||||
| CAEN Financial Year |
3314
|
|||||||||
Comments - Ultramarine Embryogenesis S.r.l.